These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 20616701)

  • 1. Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer.
    Oostendorp LJ; Stalmeier PF; Pasker-de Jong PC; Van der Graaf WT; Ottevanger PB
    Anticancer Drugs; 2010 Sep; 21(8):749-58. PubMed ID: 20616701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefit-risk assessment of irinotecan in advanced colorectal cancer.
    Glimelius B
    Drug Saf; 2005; 28(5):417-33. PubMed ID: 15853443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Mitry E; Ducreux M; Rougier P
    Bull Cancer; 1998 Dec; Spec No():38-42. PubMed ID: 9932083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
    Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irinotecan in the treatment of colorectal cancer: clinical overview.
    Vanhoefer U; Harstrick A; Achterrath W; Cao S; Seeber S; Rustum YM
    J Clin Oncol; 2001 Mar; 19(5):1501-18. PubMed ID: 11230497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
    Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
    J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial.
    Gibbs P; Clingan PR; Ganju V; Strickland AH; Wong SS; Tebbutt NC; Underhill CR; Fox RM; Clavant SP; Leung J; Pho M; Brown TJ
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):153-63. PubMed ID: 20333384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CPT-11: new drug for metastatic colorectal cancer].
    Barone C; Pozzo C; Cassano A
    Tumori; 1999; 85(6):A1-11. PubMed ID: 10774581
    [No Abstract]   [Full Text] [Related]  

  • 9. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Wiseman LR; Markham A
    Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irinotecan: toward clinical end points in drug development.
    Pazdur R
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):13-21. PubMed ID: 9726086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
    Van Cutsem E; Blijham GH
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):13-20. PubMed ID: 10213010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Van Cutsem E; Peeters M
    Bull Cancer; 1998 Dec; Spec No():33-7. PubMed ID: 9932082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Rougier P; Van Cutsem E; Bajetta E; Niederle N; Possinger K; Labianca R; Navarro M; Morant R; Bleiberg H; Wils J; Awad L; Herait P; Jacques C
    Lancet; 1998 Oct; 352(9138):1407-12. PubMed ID: 9807986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups.
    Freyer G; Rougier P; Bugat R; Droz JP; Marty M; Bleiberg H; Mignard D; Awad L; Herait P; Culine S; Trillet-Lenoir V
    Br J Cancer; 2000 Aug; 83(4):431-7. PubMed ID: 10945486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irinotecan in the first-line treatment of colorectal cancer.
    Saltz LB
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):54-8. PubMed ID: 9726092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US pivotal studies of irinotecan in colorectal carcinoma.
    Pitot HC
    Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):48-53. PubMed ID: 9726091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
    Cunningham D; Pyrhönen S; James RD; Punt CJ; Hickish TF; Heikkila R; Johannesen TB; Starkhammar H; Topham CA; Awad L; Jacques C; Herait P
    Lancet; 1998 Oct; 352(9138):1413-8. PubMed ID: 9807987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
    Cunningham D
    Semin Oncol; 1999 Feb; 26(1 Suppl 5):1-5. PubMed ID: 10213008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
    Rothenberg ML; Cox JV; DeVore RF; Hainsworth JD; Pazdur R; Rivkin SE; Macdonald JS; Geyer CE; Sandbach J; Wolf DL; Mohrland JS; Elfring GL; Miller LL; Von Hoff DD
    Cancer; 1999 Feb; 85(4):786-95. PubMed ID: 10091755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.